• This manuscript describes the clinical utility and impact of testing for HSV and syphilis in a single sample using a single test.
Key messages:
• This manuscript describes the clinical utility and impact of testing for HSV and syphilis in a single sample using a single test.
• Using this single test leads to the detection of unexpected cases of syphilis where the suspected aetiological agent was HSV, and also improves the detection rates of primary syphilis.
• The test is likely to reduce costs and turn around times as testing is performed at a single location for both pathogens and only one sample is needed.
Introduction
It is important to be able to diagnose herpes simplex virus (HSV) CAGCATGGAGAGCCCGCACG-tamra at concentrations of 100µM (primers) and 20µM
(probe) using standard taqman conditions 7 . This test was then multiplexed with the existing HSV 1/2 real-time PCR test in place at the WoSSVC which uses the fluorophores FAM and Cy5 (previously published 8 ).
Prior to the clinical evaluation, the performance of the new multiplex was validated in the laboratory using a number of different panels. Firstly a dilution series of HSV1 and HSV2
was tested using the HSV1 and 2 duplex assay and the newly developed multiplex assay to ensure that the HSV PCR component was not affected by the addition on the syphilis primers and probe. Following this, the specificity of the multiplex assay was assessed by testing a panel containing other viruses and bacteria. A dilution series of a clinical sample containing T. pallidum (provided by the SBSTIRL and previously tested by an alternative reference assay) was also tested to ensure that the newly developed multiplex achieved the same end point detection limit for syphilis testing as the reference test already in place in the SBSTIRL.
Quality assurance panels were also tested to assess the robustness and reproducibility of the newly designed multiplex assay in the laboratory.
All samples were extracted using the virus kit on the MDX extractor (Qiagen) and tested using the new triplex real-time PCR assay using UGD platinum supermix (Invitrogen) on the ABI 7500 (Applied Biosystems).
Patients and samples
Clinical samples were obtained from patients presenting to the Sandyford Initiative with symptoms of genital ulceration or suspected early syphilis, in cases where an ulcer swab would usually have been taken. During initial clinical use (6 months), 692 samples (including genital, oral and anorectal swabs) were received.
All samples were processed as outlined above. All positive syphilis PCR samples were sent to the SBSTIRL for confirmatory PCR before reporting. The T. pallidum PCR test used at the reference laboratory targets the polA gene and has been previously published 10 . The PCR results were then aligned with DGM and serological results and analysed. Serological screening was performed using a combined IgG/IgM kit (Newmarket).
Results:
The initial validation showed that the HSV components of the newly developed multiplex assay had the same endpoint detection limits as the HSV 1 and 2 duplex assay already in place in the WoSSVC. The syphilis component was also shown to have the same endpoint detection limit as the syphilis reference test in place at the SBSTIRL. No cross reactions were observed when the sensitivity panel was tested and the multiplex produced reproducible results in the ongoing EQA.
The results of the 692 clinical samples are shown in table 1 The 16 syphilis PCR positive samples were from 15 patients and were all confirmed by the SBSTIRL. Of the 15 positive patients; 12 had a blood sample taken for serological testing on their first visit; of which 10 were positive (sensitivity 83.3% compared to PCR). The remainder, who were either sero-negative on their first visit or had no blood taken, all had positive syphilis serology on follow-up serological testing.
Only six of the 15 PCR positive patients were tested by DGM yielding three positives (50% sensitivity). During the study period, all cases of primary syphilis, diagnosed by the non-PCR tests (DGM/ serology) were reviewed to check if any of them had been missed by the PCR. The reviews showed that the PCR did not miss any cases.
Discussion:
The HSV1/HSV2/T. pallidum PCR had better detection rates for primary syphilis than both DGM and serology. In addition, the T. pallidum component of the new multiplex test was shown to perform well in comparison to the PCR already in place at the SBSTIRL. Less than half of the patients with PCR-proven primary syphilis had DGM testing performed, illustrating the difficulty of relying on this alone. DGM at the Sandyford is performed by a highly-experienced full-time laboratory biomedical scientist, but even here sensitivity was just 50% compared to PCR.
The multiplex PCR test is targeted at symptomatic patients so can be used as a valuable front line test to ensure primary syphilis infection is not missed or misdiagnosed; and that serological follow-up and patient review is carried out. In two of the syphilis positive patients during this study period, follow up and blood sampling was only initiated due to the positive PCR result. In one case, a young heterosexual woman with documented previous HSV2 was unexpectedly found to be T. pallidum positive when an HSV2 recurrence had been suspected.
Previously, separate swabs had to be taken and transported to the reference laboratory for syphilis testing. As syphilis and HSV testing is now performed using a single sample at a local laboratory, it is likely that the turnaround time and costs have been reduced as well as the number of misdiagnoses.
The multiplex assay covers the huge majority of diagnosable causes of genital ulceration in the UK. Additional targets might eventually include C. trachomatis (LGV serovars) which now generally presents as severe proctitis, although some classical genital ulceration is seen 11 , and H ducreyi 12 , which remains very rare in the UK. However, care should be taken to ensure that there is no loss of sensitivity when increasing PCR targets 13 .
Conclusions:
Multiplex PCR testing for HSV1, HSV2 and T. pallidum on ulcer swabs can be incorporated into routine laboratory workflows, improving detection rates and reducing turnaround times and costs, ultimately reducing the risk of onwards transmission of primary syphilis and development of sequelae.
